New Blood Pressure Drug Could Benefit Resistant Patients
The drug lorundrostat helped some adults with uncontrolled hypertension reach target blood pressure levels in clinical trials.
Updated on Oct. 15, 2026 in Heart Disease
Live Poll
Do you trust pharmaceutical companies to prioritize patient health outcomes over their drug development goals?
Clinical trial results for the experimental drug lorundrostat show it can significantly reduce systolic blood pressure in patients with hypertension. While the drug effectively lowered blood pressure in two separate trials, it failed to improve obstructive sleep apnea symptoms.
Why it matters
Managing uncontrolled or treatment-resistant hypertension is a major challenge for many patients, and these findings offer a potential new pharmacological approach to lowering cardiovascular risk. The data provides a clearer picture of how this specific inhibitor impacts blood pressure versus other related conditions.
The findings come from randomized, double-blind, placebo-controlled trials, including the Launch-HTN and Explore-OSA studies. While participants saw significant systolic blood pressure reductions, the Explore-OSA trial showed no measurable change in the apnea-hypopnea index compared to placebo.
The players
Mineralys Therapeutics
A Radnor, Pennsylvania-based pharmaceutical company focused on developing therapies for hypertension and related cardiovascular diseases.
The details
Lorundrostat works as an oral aldosterone synthase inhibitor by targeting the CYP11B2 enzyme. By inhibiting this enzyme, the drug reduces the production of aldosterone, a hormone that regulates salt and water balance in the body, which can otherwise cause blood pressure to rise. The clinical trials evaluated daily doses of 50 and 100 milligrams to determine if this mechanism could successfully manage uncontrolled hypertension in patients.
Timeline
The American Heart Association Hypertension Scientific Sessions occurred in 2026.
Health Landscape
This development follows the rigorous evaluation patterns seen in major cardiovascular studies like the ORION-10 statin trial. It represents an effort to expand the pharmacologic toolkit for treating hypertension beyond existing standard-of-care options.
If you are currently managing treatment-resistant hypertension, these findings offer a new area of research to discuss with your physician. It is important to note that while blood pressure improved, the drug did not address sleep apnea, so patients should continue to monitor all cardiovascular symptoms under professional guidance.
The takeaway
Lorundrostat shows promise as a tool to help lower systolic blood pressure in patients who have not responded to standard treatments. If you struggle with uncontrolled hypertension, talk to your doctor about new clinical research and which blood pressure metrics are most important for you to track at home.
Further reading
Learn more about current approaches to managing high blood pressure in our Heart Disease section.
Source note: This article includes information reported by MyChesCo.
Live Poll
Do you trust pharmaceutical companies to prioritize patient health outcomes over their drug development goals?
